New Targets and Treatment for Anemia in Chronic Kidney Disease

This activity is part 2 in a 3-part webinar series.

Program Description

Several underlying mechanisms are involved in the systemic inflammation of chronic kidney disease (CKD) and its associated comorbidities, including anemia. The hypoxia-inducible factor (HIF) system plays a central role in CKD and has emerged as a treatment target. Though several guidelines on the management of anemia in CKD are available, most have not been recently updated, and ideal recommendations for management of anemia in CKD vary widely. Current standard treatment for anemia in CKD includes intravenous iron supplementation and erythropoiesis-stimulating agents; however, the focus is now on inhibiting the HIF pathway with the new and emerging HIF prolyl hydroxylase inhibitors, which are oral formulations. This module will provide pharmacists with a review of clinical data for recently approved and investigational HIF prolyl hydroxylase inhibitors, with a focus on key educational points for administration considerations, management of adverse effects, and clinical pearls for the transition of patients with anemia in CKD from intravenous to oral therapies.

Target audience: Health-system, retail, and specialty pharmacists

Type of activity: Application
Release date: August 31, 2022
Expiration date: August 31, 2023

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Illustrate the pathophysiology of anemia in chronic kidney disease (CKD) and emerging targets
• Analyze the clinical data for the emerging HIF-PHIs for anemia treatment in CKD
• Adapt guideline updates and current clinical data into alternative treatment strategies

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-406-H01-P. The activity is available for CE credit through August 31, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Calvin Meaney, PharmD, BCPS, has the following financial relationships with commercial interests to disclose:
Consultant: GlaxoSmithKline, Vifor Pharma, Inc.

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, MBA, CHCP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms